352 related articles for article (PubMed ID: 27434126)
1. Current relevance of hypoxia in head and neck cancer.
Bredell MG; Ernst J; El-Kochairi I; Dahlem Y; Ikenberg K; Schumann DM
Oncotarget; 2016 Aug; 7(31):50781-50804. PubMed ID: 27434126
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Jonathan RA; Wijffels KI; Peeters W; de Wilde PC; Marres HA; Merkx MA; Oosterwijk E; van der Kogel AJ; Kaanders JH
Radiother Oncol; 2006 Jun; 79(3):288-97. PubMed ID: 16730088
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
De Schutter H; Landuyt W; Verbeken E; Goethals L; Hermans R; Nuyts S
BMC Cancer; 2005 Apr; 5():42. PubMed ID: 15847702
[TBL] [Abstract][Full Text] [Related]
5. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer.
Winter SC; Shah KA; Han C; Campo L; Turley H; Leek R; Corbridge RJ; Cox GJ; Harris AL
Cancer; 2006 Aug; 107(4):757-66. PubMed ID: 16826581
[TBL] [Abstract][Full Text] [Related]
6. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Nordsmark M; Eriksen JG; Gebski V; Alsner J; Horsman MR; Overgaard J
Radiother Oncol; 2007 Jun; 83(3):389-97. PubMed ID: 17499868
[TBL] [Abstract][Full Text] [Related]
7. Is the hypoxia-inducible factor pathway important in gastric cancer?
Griffiths EA; Pritchard SA; Welch IM; Price PM; West CM
Eur J Cancer; 2005 Dec; 41(18):2792-805. PubMed ID: 16290133
[TBL] [Abstract][Full Text] [Related]
8. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.
Gillespie DL; Aguirre MT; Ravichandran S; Leishman LL; Berrondo C; Gamboa JT; Wang L; King R; Wang X; Tan M; Malamas A; Lu ZR; Jensen RL
J Neurosurg; 2015 Feb; 122(2):331-41. PubMed ID: 25423275
[TBL] [Abstract][Full Text] [Related]
9. p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer.
Vleugel MM; Shvarts D; van der Wall E; van Diest PJ
Hum Pathol; 2006 Aug; 37(8):1085-92. PubMed ID: 16867872
[TBL] [Abstract][Full Text] [Related]
10. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
11. Levels and patterns of expression of hypoxia-inducible factor-1α, vascular endothelial growth factor, glucose transporter-1 and CD105 in adenoid cystic carcinomas with high-grade transformation.
Costa AF; Tasso MG; Mariano FV; Soares AB; Chone CT; Crespo AN; Fresno MF; Llorente JL; Suárez C; de Araújo VC; Hermsen M; Altemani A
Histopathology; 2012 Apr; 60(5):816-25. PubMed ID: 22320429
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review.
Hoogsteen IJ; Marres HA; Bussink J; van der Kogel AJ; Kaanders JH
Head Neck; 2007 Jun; 29(6):591-604. PubMed ID: 17252597
[TBL] [Abstract][Full Text] [Related]
13. Risk prediction for malignant conversion of oral epithelial dysplasia by hypoxia related protein expression.
Zhang X; Han S; Han HY; Ryu MH; Kim KY; Choi EJ; Cha IH; Kim J
Pathology; 2013 Aug; 45(5):478-83. PubMed ID: 23811806
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Hui EP; Chan AT; Pezzella F; Turley H; To KF; Poon TC; Zee B; Mo F; Teo PM; Huang DP; Gatter KC; Johnson PJ; Harris AL
Clin Cancer Res; 2002 Aug; 8(8):2595-604. PubMed ID: 12171890
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of hypoxia markers in T2-staged oral tongue cancer.
Roh JL; Cho KJ; Kwon GY; Ryu CH; Chang HW; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Jan; 45(1):63-8. PubMed ID: 18620902
[TBL] [Abstract][Full Text] [Related]
16. Tumor hypoxia and role of hypoxia-inducible factor in oral cancer.
Singh P; Rajput M; Pandey M
World J Surg Oncol; 2024 Jan; 22(1):18. PubMed ID: 38200568
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factors in OSCC.
Pérez-Sayáns M; Suárez-Peñaranda JM; Pilar GD; Barros-Angueira F; Gándara-Rey JM; García-García A
Cancer Lett; 2011 Dec; 313(1):1-8. PubMed ID: 21959110
[TBL] [Abstract][Full Text] [Related]
18. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
Koukourakis MI; Bentzen SM; Giatromanolaki A; Wilson GD; Daley FM; Saunders MI; Dische S; Sivridis E; Harris AL
J Clin Oncol; 2006 Feb; 24(5):727-35. PubMed ID: 16418497
[TBL] [Abstract][Full Text] [Related]
19. Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation.
Jensen R; Lee J
Neurosurgery; 2012 Jul; 71(1):146-56. PubMed ID: 22472549
[TBL] [Abstract][Full Text] [Related]
20. Endogenous hypoxia markers: case not proven!
Mayer A; Höckel M; Vaupel P
Adv Exp Med Biol; 2008; 614():127-36. PubMed ID: 18290322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
